Guru P. Sonpavde, MD

AdventHealth Cancer Institute; University of Central Florida

Orlando, Florida

Guru P. Sonpavde, MD, is the Director of Genitourinary Oncology, Director of Phase I Clinical Trials, Assistant Director of the Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando, Florida. Additionally, he holds a position of Professor of Medicine at both the University of Central Florida in Orlando and Loma Linda University Health in California. His focus is on drug development, including the evaluation of immunotherapy, targeted therapy, antibody-drug conjugates, and translational research to cure genitourinary cancers. He serves on the steering committees of several pivotal phase III trials evaluating treatments for bladder cancer. Under his leadership, the Phase I and GU Oncology program has grown robustly at the AdventHealth Cancer Institute.

Dr. Sonpavde earned his medical degree at Christian Medical College in Vellore, India. He completed a residency in Internal Medicine at Nassau University Medical Center in East Meadow, New York. Dr. Sonpavde then completed a fellowship in Hematology and Oncology at Indiana University Medical Center in Indianapolis, Indiana.

Dr. Sonpavde is a member of the Southwest Oncology Group, the Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of the US NCI GU Steering Committee. He has published over 849 articles and book chapters and has contributed to or has been cited in video and written cancer education portals, including Uptodate®, Practice Update, Onclive, Physician Education Resource (PER), and Research to Practice. He has also been cited in several lay magazine articles -- most notably in TIME magazine regarding participation in clinical trials in August of 2022.